Stay updated on ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page.

Latest updates to the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page
- Check2 days agoChange DetectedThe clinical trial record for the Abraxane and pembrolizumab study in advanced urothelial cancer is now displayed, including study design, participation criteria, outcome measures, and study documents. The previous 403 error page is gone.SummaryDifference49%

- Check9 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check16 days agoChange DetectedA notice about NIH’s terminology transition appears above the ClinicalTrials.gov page, which still shows a 403 Forbidden error instead of the study record.SummaryDifference1%

- Check23 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check29 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check51 days agoChange DetectedA new Revision: v3.7.0 is added to the page. A large set of study documents and related items, including Informed Consent Form entries and the Study Protocol/SAP, were removed from the Study Documents section.SummaryDifference18%

Stay in the know with updates to ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page.